This research demonstrates that Ac-SDKP (a TB4 fragment) effectively blocks silica-induced pulmonary fibrosis by inhibiting ALKBH1, an enzyme that suppresses protective microRNA (miR-129-5p) expression. The study identifies a novel epigenetic mechanism—m6A demethylation—as the pathological driver of fibrosis, and shows Ac-SDKP reverses this process to restore antifibrotic miRNA levels. For practitioners, this provides mechanistic validation that peptide-based therapeutics can modulate RNA-level disease pathways in a serious occupational lung disease with no current effective treatment.
For your business
Ac-SDKP may counter silica-driven lung fibrosis via epigenetic miRNA regulation, supporting peptide use in occupational lung disease.